GB9900334D0
(en)
*
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
PL205557B1
(pl)
|
1999-02-10 |
2010-05-31 |
Astrazeneca Ab |
Pochodne indolu
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
EE200200565A
(et)
*
|
2000-03-31 |
2004-06-15 |
Angiogene Pharmaceuticals Ltd. |
Vaskulaarse kahjustava toimega kombinatsioonravi
|
DE60111622T2
(de)
*
|
2000-03-31 |
2006-05-18 |
Angiogene Pharmaceuticals Ltd. |
Getrennte dosis therapien mit gefässschädigender aktivität
|
NZ522074A
(en)
*
|
2000-05-31 |
2004-06-25 |
Astrazeneca Ab |
Indole derivatives with vascular damaging activity
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
MXPA02012905A
(es)
*
|
2000-07-07 |
2004-07-30 |
Angiogene Pharm Ltd |
Derivados de colquinol como agentes de dano vascular..
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
IL153325A0
(en)
*
|
2000-07-07 |
2003-07-06 |
Angiogene Pharm Ltd |
Colchinol derivatives as angiogenesis inhibitors
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
US20040229960A1
(en)
*
|
2001-07-13 |
2004-11-18 |
David Sherris |
Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
|
US6919324B2
(en)
|
2001-10-26 |
2005-07-19 |
Oxigene, Inc. |
Functionalized stilbene derivatives as improved vascular targeting agents
|
RU2362774C1
(ru)
|
2002-02-01 |
2009-07-27 |
Астразенека Аб |
Хиназолиновые соединения
|
US20050215530A1
(en)
*
|
2002-04-16 |
2005-09-29 |
Ryan Anderson J |
Combination therapy for the treatment of cancer
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
ATE381546T1
(de)
|
2002-08-24 |
2008-01-15 |
Astrazeneca Ab |
Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
GB0223379D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Angiogene Pharm Ltd |
Combination therapy
|
FR2848212B1
(fr)
*
|
2002-12-06 |
2006-10-27 |
Aventis Pharma Sa |
Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
|
DE60315892T2
(de)
|
2002-12-24 |
2008-08-14 |
Astrazeneca Ab |
Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
|
US7655646B2
(en)
*
|
2003-01-21 |
2010-02-02 |
Thallion Pharmaceuticals, Inc. |
Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
|
WO2004078126A2
(en)
|
2003-02-28 |
2004-09-16 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
MXPA05013827A
(es)
*
|
2003-06-18 |
2006-03-13 |
Angiogene Pharm Ltd |
Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g.
|
GB0316123D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
GB0318422D0
(en)
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
US7598383B2
(en)
|
2003-11-19 |
2009-10-06 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
GB0329771D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Angiogene Pharm Ltd |
Chemical processes & intermediates
|
DE602004031777D1
(en)
|
2004-01-05 |
2011-04-21 |
Astrazeneca Ab |
Thiophenderivate als chk-1-inhibitoren
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
BRPI0514735B8
(pt)
|
2004-08-28 |
2021-05-25 |
Astrazeneca Ab |
derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
|
EP2284194A1
(en)
|
2004-12-21 |
2011-02-16 |
AstraZeneca AB |
Antibodies directed to angiopoietin-2 and uses thereof
|
SI2383268T1
(sl)
|
2005-02-04 |
2016-02-29 |
Astrazeneca Ab |
Derivati pirazolilaminopiridina uporabni kot kinazni inhibitorji
|
CN102942522A
(zh)
|
2005-05-18 |
2013-02-27 |
阵列生物制药公司 |
Mek的杂环抑制剂及其使用方法
|
EP2402316A1
(en)
|
2005-07-21 |
2012-01-04 |
AstraZeneca AB (Publ) |
Piperidine derivatives
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
EP1939198A4
(en)
|
2005-09-22 |
2012-02-15 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
JPWO2007034882A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
WO2007034917A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規なアデニン化合物
|
EP1939200A4
(en)
|
2005-09-22 |
2010-06-16 |
Dainippon Sumitomo Pharma Co |
NEW ADENINE CONNECTION
|
US7384935B2
(en)
*
|
2005-09-27 |
2008-06-10 |
Thallion Pharmaceuticals, Inc. |
Phosphate prodrugs of a farnesyl dibenzodiazepinone, processes for their production and their use as pharmaceuticals
|
JP5155171B2
(ja)
|
2005-10-06 |
2013-02-27 |
アストラゼネカ・アクチエボラーグ |
新規化合物
|
ES2391783T3
(es)
|
2005-10-28 |
2012-11-29 |
Astrazeneca Ab |
Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
|
PL1971601T3
(pl)
|
2005-11-15 |
2010-03-31 |
Array Biopharma Inc |
Pochodne N4-fenylo-chinazolino-4-aminy i związki pokrewne jako inhibitory receptorowych kinaz tyrozynowych ErbB typu I do leczenia chorób cechujących się nadmierną proliferacją komórek
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
ES2385054T3
(es)
|
2005-12-13 |
2012-07-17 |
Medimmune Limited |
Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas
|
EP2305640A3
(en)
|
2005-12-15 |
2011-07-20 |
AstraZeneca AB |
Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
US7741360B2
(en)
|
2006-05-26 |
2010-06-22 |
Astrazeneca Ab |
Bi-aryl or aryl-heteroaryl substituted indoles
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
JP5227321B2
(ja)
*
|
2006-08-23 |
2013-07-03 |
クドス ファーマシューティカルズ リミテッド |
Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
US20100113510A1
(en)
|
2006-12-19 |
2010-05-06 |
Rhonan Ford |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
JPWO2008114819A1
(ja)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
KR20100087147A
(ko)
|
2007-10-04 |
2010-08-03 |
아스트라제네카 아베 |
글루코코르티코이드 활성을 갖는 스테로이드성 [3,2-c]피라졸 화합물
|
PL2201012T3
(pl)
|
2007-10-11 |
2014-11-28 |
Astrazeneca Ab |
Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
|
AU2008326251B2
(en)
|
2007-11-21 |
2014-03-06 |
Mateon Therapeutics, Inc. |
Method for treating hematopoietic neoplasms
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
KR101759457B1
(ko)
|
2007-12-21 |
2017-07-31 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
NZ586872A
(en)
|
2008-02-06 |
2012-03-30 |
Astrazeneca Ab |
Spirocyclic amide compounds
|
WO2009108670A1
(en)
|
2008-02-28 |
2009-09-03 |
Merck Serono S.A. |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
CN102105448B
(zh)
|
2008-05-27 |
2013-11-13 |
阿斯利康(瑞典)有限公司 |
苯氧基吡啶基酰胺衍生物和它们在治疗由pde4介导的病症中的用途
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
KR101849059B1
(ko)
|
2008-12-11 |
2018-04-13 |
악센투아 파마슈투칼스 아베 |
제니스테인의 결정성 형태
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
JP2012512246A
(ja)
|
2008-12-17 |
2012-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C環修飾型三環式ベンゾナフチリジノン・タンパク質キナーゼ阻害薬及びこれらの使用
|
WO2010080253A1
(en)
|
2008-12-18 |
2010-07-15 |
Merck Patent Gmbh |
Tricyclic azaindoles
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
JP5059977B2
(ja)
|
2009-02-10 |
2012-10-31 |
アストラゼネカ アクチボラグ |
トリアゾロ[4,3−b]ピリダジン誘導体および前立腺癌のためのそれらの使用
|
WO2010103094A1
(en)
|
2009-03-13 |
2010-09-16 |
Cellzome Limited |
PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
EP2419423A1
(en)
|
2009-04-14 |
2012-02-22 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
EP2475648A1
(en)
|
2009-09-11 |
2012-07-18 |
Cellzome Limited |
Ortho substituted pyrimidine compounds as jak inhibitors
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
CN102639505A
(zh)
|
2009-10-02 |
2012-08-15 |
阿斯利康(瑞典)有限公司 |
用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
NZ598907A
(en)
|
2009-10-20 |
2014-03-28 |
Cellzome Ltd |
Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
IN2012DN03391A
(no)
|
2009-11-18 |
2015-10-23 |
Astrazeneca Ab |
|
CA2992770A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmune Limited |
Targeted binding agents against b7-h1
|
WO2011068233A1
(en)
|
2009-12-03 |
2011-06-09 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
BR112012014164A2
(pt)
|
2009-12-14 |
2016-05-17 |
Merck Patent Gmbh |
inibidores da esfingosina quinase
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
BR112012014884A2
(pt)
|
2009-12-17 |
2016-03-22 |
Merck Patent Gmbh |
inibidores de esfingosina quinase
|
EP2523966B1
(en)
|
2010-01-15 |
2017-10-04 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
MX2012008328A
(es)
|
2010-01-19 |
2012-08-08 |
Astrazeneca Ab |
Derivados de pirazina.
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
ES2535116T3
(es)
|
2010-03-04 |
2015-05-05 |
Cellzome Limited |
Derivados de urea sustituida con morfolino como inhibidores de mtor
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
EA201291038A1
(ru)
|
2010-04-30 |
2013-05-30 |
Целльзом Лимитид |
Соединения пиразола в качестве ингибиторов jak
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
CA2799653A1
(en)
|
2010-06-04 |
2011-12-08 |
Bertrand Leblond |
Substituted isoquinolines and their use as tubulin polymerization inhibitors
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
WO2012000970A1
(en)
|
2010-07-01 |
2012-01-05 |
Cellzome Limited |
Triazolopyridines as tyk2 inhibitors
|
TW201219383A
(en)
|
2010-08-02 |
2012-05-16 |
Astrazeneca Ab |
Chemical compounds
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
JP2013534233A
(ja)
|
2010-08-20 |
2013-09-02 |
セルゾーム リミティッド |
選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
|
CN102656179B
(zh)
|
2010-08-28 |
2015-07-29 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
JP2014500254A
(ja)
|
2010-11-09 |
2014-01-09 |
セルゾーム リミティッド |
Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
EP2640716A1
(en)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
US8895570B2
(en)
|
2010-12-17 |
2014-11-25 |
Astrazeneca Ab |
Purine derivatives
|
BR112013015508B1
(pt)
|
2010-12-20 |
2022-04-05 |
Medimmune Limited |
Molécula de anticorpo para il-18 humana, domínio vh isolado e domínio vl isolado, composição, uso de uma molécula de anticorpo ou do domínio vh isolado e do domínio vl isolado, molécula de ácido nucleico isolada, célula hospedeira procariótica recombinante, método para produzir um anticorpo, e método in vitro para medir il-18 em uma amostra de um indivíduo
|
CN103619865B
(zh)
|
2011-02-02 |
2016-10-12 |
苏州润新生物科技有限公司 |
某些化学个体、组合物及方法
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
US9174946B2
(en)
|
2011-02-17 |
2015-11-03 |
Cancer Therapeutics Crc Pty Ltd |
Selective FAK inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
JP2014510122A
(ja)
|
2011-04-04 |
2014-04-24 |
セルゾーム リミテッド |
mTOR阻害剤としてのジヒドロピロロピリミジン誘導体
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
CN103781781B
(zh)
|
2011-07-12 |
2015-08-26 |
阿斯利康(瑞典)有限公司 |
作为趋化因子受体调节剂的n-(6-((2r,3s)-3,4-二羟基丁-2-基氧基)-2-(4-氟苄基硫基)嘧啶-4-基)-3-甲基氮杂环丁烷-1-磺酰胺
|
SI2736895T1
(sl)
|
2011-07-27 |
2016-03-31 |
Astrazeneca Ab |
Derivati 2-(2,4,5-substituiranega-anilino) pirimidina, kot modulatorji EGFR uporabni za zdravljenje raka
|
EP2736901A1
(en)
|
2011-07-28 |
2014-06-04 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
CA2846574C
(en)
|
2011-08-26 |
2020-07-07 |
Neupharma, Inc. |
Quinoxaline sulfonamide derivates for use as kinase inhibitors
|
CN104080335B
(zh)
|
2011-09-01 |
2017-06-09 |
钱向平 |
某些化学实体、组合物及方法
|
CA2848506C
(en)
|
2011-09-14 |
2020-07-21 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CN103874699A
(zh)
|
2011-09-20 |
2014-06-18 |
赛尔佐姆有限公司 |
吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
|
JP5995975B2
(ja)
|
2011-09-21 |
2016-09-21 |
セルゾーム リミテッド |
Mtor阻害剤としてのモルホリノ置換尿素またはカルバメート誘導体
|
WO2013043935A1
(en)
|
2011-09-21 |
2013-03-28 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9242993B2
(en)
|
2011-10-07 |
2016-01-26 |
Cellzome Limited |
Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
RU2014130214A
(ru)
|
2011-12-23 |
2016-02-10 |
Целльзом Лимитид |
Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
|
WO2013112950A2
(en)
|
2012-01-25 |
2013-08-01 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
AU2012367141B2
(en)
|
2012-01-28 |
2016-12-22 |
Merck Patent Gmbh |
Triazolo[4,5-d]pyrimidine derivatives
|
HUE032203T2
(en)
|
2012-02-09 |
2017-08-28 |
Merck Patent Gmbh |
Furo- [3,2-b] pyridine derivatives as TBK1 and IKK inhibitors
|
NZ630170A
(en)
|
2012-02-09 |
2016-03-31 |
Merck Patent Gmbh |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
ES2674451T3
(es)
|
2012-02-21 |
2018-06-29 |
Merck Patent Gmbh |
2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
|
CA2863717C
(en)
|
2012-02-21 |
2021-09-28 |
Lars Burgdorf |
Furopyridine derivatives
|
CN104254531B
(zh)
|
2012-02-21 |
2017-05-03 |
默克专利股份公司 |
环状二氨基嘧啶衍生物
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
BR112014024903A2
(pt)
|
2012-04-05 |
2017-07-11 |
Hoffmann La Roche |
anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
|
CN109354598A
(zh)
|
2012-04-29 |
2019-02-19 |
润新生物公司 |
化学个体、药物组合物及癌症治疗方法
|
JP6097820B2
(ja)
|
2012-05-04 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
ピロロトリアジノン誘導体
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
EP2877485B1
(de)
|
2012-07-24 |
2018-03-14 |
Merck Patent GmbH |
Hydroxystatin-derivate zur behandlung von arthrose
|
CN104507942B
(zh)
|
2012-08-07 |
2017-03-22 |
默克专利股份公司 |
作为蛋白质激酶抑制剂的吡啶并嘧啶衍生物
|
CA2881330C
(en)
|
2012-08-08 |
2020-07-21 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
CA2882158A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
CN102898330B
(zh)
*
|
2012-09-03 |
2015-02-25 |
浙江大学 |
秋水仙碱衍生物
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
WO2014045101A1
(en)
|
2012-09-21 |
2014-03-27 |
Cellzome Gmbh |
Tetrazolo quinoxaline derivatives as tankyrase inhibitors
|
EP2897618B1
(en)
|
2012-09-24 |
2021-11-17 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2900643B1
(en)
|
2012-09-26 |
2017-09-27 |
Merck Patent GmbH |
Quinazolinone derivatives as parp inhibitors
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
ES2674928T3
(es)
|
2012-11-05 |
2018-07-05 |
Gmdx Co Pty Ltd |
Métodos para determinar la causa de la mutagénesis somática
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
US9732032B2
(en)
|
2012-11-16 |
2017-08-15 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
EP2951177B1
(en)
|
2013-01-31 |
2018-04-04 |
Neomed Institute |
Imidazopyridine compounds and uses thereof
|
WO2014127881A1
(de)
|
2013-02-25 |
2014-08-28 |
Merck Patent Gmbh |
2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
US9617266B2
(en)
|
2013-03-05 |
2017-04-11 |
Merck Patent Gmbh |
Imidazopyrimidine derivatives
|
JP2016513735A
(ja)
|
2013-03-15 |
2016-05-16 |
マグシューティクス,インコーポレイテッド |
癌のためのマグネシウム組成物およびその使用
|
AU2014228822A1
(en)
|
2013-03-15 |
2015-10-01 |
Memorial Sloan-Kettering Cancer Center |
HSP90-targeted cardiac imaging and therapy
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
CA2916533C
(en)
|
2013-06-25 |
2022-12-20 |
University Of Canberra |
Methods and compositions for modulating cancer stem cells
|
PL3035936T3
(pl)
|
2013-08-23 |
2019-08-30 |
Neupharma, Inc. |
Pewne jednostki chemiczne, kompozycje i sposoby
|
CN105764513A
(zh)
|
2013-09-18 |
2016-07-13 |
堪培拉大学 |
干细胞调控ii
|
WO2015048852A1
(en)
|
2013-10-01 |
2015-04-09 |
The University Of Queensland |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CN107106517A
(zh)
|
2014-08-25 |
2017-08-29 |
堪培拉大学 |
用于调节癌干细胞的组合物及其用途
|
ES2883628T3
(es)
|
2014-11-17 |
2021-12-09 |
Univ Queensland |
Biomarcadores de glucoproteínas para adenocarcinoma de esófago y esófago de Barrett y usos de los mismos
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
US10947201B2
(en)
|
2015-02-17 |
2021-03-16 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
WO2017020065A1
(en)
|
2015-08-04 |
2017-02-09 |
University Of South Australia |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
US11419934B2
(en)
|
2015-08-18 |
2022-08-23 |
Oncotelic Therapeutics, Inc. |
Use of VDAS to enhance immunomodulating therapies against tumors
|
CN116574809A
(zh)
|
2015-08-26 |
2023-08-11 |
Gmdx私人有限公司 |
检测癌症复发的方法
|
WO2017106926A1
(en)
|
2015-12-23 |
2017-06-29 |
Queensland University Of Technology |
Nucleic acid oligomers and uses therefor
|
SG11201806122YA
(en)
|
2016-02-01 |
2018-08-30 |
Univ Canberra |
Proteinaceous compounds and uses therefor
|
CA3014674C
(en)
|
2016-02-15 |
2024-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods comprising fixed intermittent dosing of cediranib
|
PL3442535T3
(pl)
|
2016-04-15 |
2022-10-24 |
Cancer Research Technology Limited |
Związki heterocykliczne jako inhibitory kinazy ret
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
PT3490565T
(pt)
|
2016-07-29 |
2022-09-06 |
Rapt Therapeutics Inc |
Derivados de azetidina como moduladores dos recetores de quimiocinas e suas utilizações
|
US10544106B2
(en)
|
2016-08-15 |
2020-01-28 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US10919896B2
(en)
|
2016-09-22 |
2021-02-16 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
MX2019006333A
(es)
|
2016-12-05 |
2019-09-26 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos.
|
EP3577116A4
(en)
|
2017-02-01 |
2020-12-02 |
Aucentra Therapeutics Pty Ltd |
DERIVATIVES OF N-CYCLOALKYL / HETEROCYCLOALKYL-4- (IMIDAZO [1,2-A] PYRIDINE) PYRIMIDINE-2-AMINE AS THERAPEUTICS
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
EP3630749B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
IL270869B2
(en)
|
2017-05-26 |
2023-09-01 |
Cancer Research Tech Ltd |
Benzimidazolone derivative inhibitors of bcl6
|
WO2018220101A1
(en)
|
2017-05-31 |
2018-12-06 |
Truly Translational Sweden Ab |
A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
WO2019007447A1
(en)
|
2017-07-05 |
2019-01-10 |
E.P.O.S Iasis Research And Development Limited |
MULTIFUNCTIONAL CONJUGATES
|
PT3661941T
(pt)
|
2017-08-01 |
2023-03-16 |
Merck Patent Gmbh |
Derivados tiazolopiridina como antagonistas do recetor de adenosina
|
US11447505B1
(en)
|
2017-08-18 |
2022-09-20 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
IL272637B2
(en)
|
2017-08-21 |
2024-03-01 |
Merck Patent Gmbh |
History of benzaimidazole, their preparation and medicines containing them
|
DK3672951T3
(da)
|
2017-08-21 |
2023-11-20 |
Merck Patent Gmbh |
Quinoxalinderivater som adenosinreceptorantagonister
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
US11730736B2
(en)
|
2017-11-06 |
2023-08-22 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
ES2965337T3
(es)
|
2017-11-23 |
2024-04-12 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Composición farmacéutica para administración oral que contiene sulfasalazina y/o una sal orgánica de sulfasalazina, proceso de producción y uso
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
CN111757881B
(zh)
|
2018-01-15 |
2024-05-07 |
澳升医药公司 |
作为治疗剂的5-(嘧啶-4-基)噻唑-2-基脲衍生物
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
AU2019212478C1
(en)
|
2018-01-26 |
2023-11-16 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
AU2019218893A1
(en)
|
2018-02-08 |
2020-09-03 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
IL296734A
(en)
|
2018-04-13 |
2022-11-01 |
The Institute Of Cancer Res Royal Cancer Hospital |
bcl6 inhibitors
|
WO2019210266A1
(en)
|
2018-04-27 |
2019-10-31 |
Spruce Biosciences, Inc. |
Methods for treating testicular and ovarian adrenal rest tumors
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
WO2019236496A1
(en)
|
2018-06-04 |
2019-12-12 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
EP4360713A3
(en)
|
2018-09-18 |
2024-05-22 |
F. Hoffmann-La Roche AG |
Quinazoline derivatives as antitumor agents
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
US20210361669A1
(en)
|
2018-10-25 |
2021-11-25 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
AU2019363662A1
(en)
|
2018-10-25 |
2021-03-25 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
WO2020132844A1
(zh)
|
2018-12-25 |
2020-07-02 |
中国医学科学院基础医学研究所 |
炎性相关疾病防治的小rna药物及其组合
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
AU2020232026A1
(en)
|
2019-03-07 |
2021-09-02 |
Merck Patent Gmbh |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
CN111747931A
(zh)
|
2019-03-29 |
2020-10-09 |
深圳福沃药业有限公司 |
用于治疗癌症的氮杂芳环酰胺衍生物
|
CN113905787A
(zh)
|
2019-04-05 |
2022-01-07 |
斯托姆治疗有限公司 |
Mettl3抑制化合物
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
WO2021037219A1
(zh)
|
2019-08-31 |
2021-03-04 |
上海奕拓医药科技有限责任公司 |
用于fgfr抑制剂的吡唑类衍生物及其制备方法
|
US20220389003A1
(en)
|
2019-09-20 |
2022-12-08 |
Ideaya Biosciences, Inc. |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
US20230116403A1
(en)
|
2019-12-02 |
2023-04-13 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as mettl3 inhibitors
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
CA3220146A1
(en)
|
2021-05-17 |
2022-11-24 |
Hk Inno.N Corporation |
Benzamide derivatives, preparation method thereof, and pharmaceutical composition for use in preventing of treating cancer containing the same as an active ingredient
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting EGFR
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
IT202100023357A1
(it)
|
2021-09-09 |
2023-03-09 |
Cheirontech S R L |
Peptidi con attività anti-angiogenica
|
EP4413000A1
(en)
|
2021-10-04 |
2024-08-14 |
FoRx Therapeutics AG |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
IL314200A
(en)
|
2022-01-10 |
2024-09-01 |
Merck Patent Gmbh |
Heterocycles are being converted as HSET inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|